Better Industry Health

Better Industry Health

Mylan cannot act alone when it comes to delivering better health for our industry. Patient needs and healthcare challenges differ around the world. That’s why Mylan works in good faith with various stakeholders and uses strong alliances with industry associations. By doing so, we’re able to facilitate development of low-cost generic pharmaceuticals and drive discussions on access for patient populations at large. Key associations with which we work include the Association for Accessible Medicines (AAM), Medicines for Europe, and the International Generic and Biosimilar Medicines Association (IGBA). Mylan also works with international groups such as the Global Pharmaceutical Manufacturers Leadership Forum, the International Society for Pharmaceutical Engineering (ISPE) and the Parenteral Drug Association (PDA) to help shape global health and drug quality policy.

Championing Access to Generics

Healthcare systems and funding vary greatly by country, but in most if not all cases, generic products are able to be provided significantly below the originator’s price, bringing benefits to patients, governments, insurers and others within the healthcare system. Below is a summary of the important role generics play in key geographies across the globe.

Industry Chart

U.S.

Mylan is the No. 2 provider of prescription medicines in the U.S. In 2017 generics represented approximately 89% of all pharmaceutical products sold in the nation.6 In contrast, generics constituted only 26% of U.S. pharmaceutical spend. A further illustration of these savings: In 2016 generics saved the U.S. healthcare system $253 billion.7 Approximately $25 billion of that amount represents savings from Mylan generics.

Europe

Over the past 10 years, generic medicines have more than doubled access in seven key therapeutic areas – without increasing overall treatment cost – benefiting millions of patients.8 In 2016 generic pharmaceuticals represented 56% of the medicines used in the region, but only 22% of total drug costs.9 The countries that make up Mylan’s business in Europe represent the world’s second largest generic pharmaceuticals market.

6Based on IQVIA MIDAS and NSP data for the 12 months ended 12/17, rank by value

7https://accessiblemeds.org/sites/default/files/2017-07/2017-AAM-Access-Savings-Report-2017-web2.pdf

8http://www.medicinesforeurope.com/generic-medicines/our-5-pillars/

9Long D., Global Generic and Biosimilars Trends and Insights. Association for Accessible Medicines, February 13, 2018